Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Wirden

Showing results (61-70 of 98) with videos related to

Pageof 10
Sort By:
The Journal of Antimicrobial Chemotherapy|March 11, 2021
No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartmentsBasma Abdi, Mouna Chebbi, Marc Wirden, et al.
Antimicrobial Agents and Chemotherapy|January 25, 2003
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patientsAnne-Geneviève Marcelin, Claire Lamotte, Constance Delaugerre, et al.
The Journal of Infectious Diseases|August 20, 2021
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected PatientsRomain Palich, Elisa Teyssou, Sophie Sayon, et al.
The Journal of Antimicrobial Chemotherapy|July 6, 2019
Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR studyMarc-Antoine Valantin, Lise Durand, Marc Wirden, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 28, 2020
Evolution of viral quasispecies during SARS-CoV-2 infectionAude Jary, Valentin Leducq, Isabelle Malet, et al.
Antiviral Research|December 6, 2011
E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutationsSlim Fourati, Isabelle Malet, Carolin A Guenzel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 29, 2021
Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare WorkersStéphane Marot, Isabelle Malet, Valentin Leducq, et al.
Plos One|August 1, 2012
Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeksSidonie Lambert-Niclot, Philippe Flandre, Marc-Antoine Valantin, et al.
Open Forum Infectious Diseases|May 25, 2019
INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow LevelsSidonie Lambert-Niclot, Anders Boyd, Djeneba Fofana, et al.
The Journal of Antimicrobial Chemotherapy|December 20, 2024
Changes in NNRTI use have not altered the ecology of NNRTI resistance over the last 10 years in people with HIV experiencing virological failure on antiretroviral drugsCathia Soulie, Rachid Agher, Antoine Fauchois, et al.
Pageof 10

Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
The Journal of Antimicrobial Chemotherapy|March 11, 2021
No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartmentsBasma Abdi, Mouna Chebbi, Marc Wirden, et al.
Antimicrobial Agents and Chemotherapy|January 25, 2003
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patientsAnne-Geneviève Marcelin, Claire Lamotte, Constance Delaugerre, et al.
The Journal of Infectious Diseases|August 20, 2021
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected PatientsRomain Palich, Elisa Teyssou, Sophie Sayon, et al.
The Journal of Antimicrobial Chemotherapy|July 6, 2019
Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR studyMarc-Antoine Valantin, Lise Durand, Marc Wirden, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 28, 2020
Evolution of viral quasispecies during SARS-CoV-2 infectionAude Jary, Valentin Leducq, Isabelle Malet, et al.
Antiviral Research|December 6, 2011
E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutationsSlim Fourati, Isabelle Malet, Carolin A Guenzel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 29, 2021
Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare WorkersStéphane Marot, Isabelle Malet, Valentin Leducq, et al.
Plos One|August 1, 2012
Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeksSidonie Lambert-Niclot, Philippe Flandre, Marc-Antoine Valantin, et al.
Open Forum Infectious Diseases|May 25, 2019
INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow LevelsSidonie Lambert-Niclot, Anders Boyd, Djeneba Fofana, et al.
The Journal of Antimicrobial Chemotherapy|December 20, 2024
Changes in NNRTI use have not altered the ecology of NNRTI resistance over the last 10 years in people with HIV experiencing virological failure on antiretroviral drugsCathia Soulie, Rachid Agher, Antoine Fauchois, et al.
Pageof 10